Rejuvenate Bio Inc. develops novel therapeutics for mitral valve disease. The firm is focused on gene therapies for dogs. Over seven million dogs in the United States alone have Mitral Valve Disease (MVD). For certain breeds, such as Cavalier King Charles Spaniels, more than 80% of dogs will be afflicted with MVD. The firm aims to change this via a cardio-protective gene therapy that holds the promise of stopping the progression of MVD.